B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Cassava Sciences (SAVA – Research Report) today and set a price target of $72.00. The company's shares closed last Wednesday at $29.50. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -21.8% and a 28.5% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. Cassava Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $98.80. See the top stocks recommended by analysts >> The company has a one-year high of $146.16 and a one-year low of $30.60.
https://www.tipranks.com/news/blurbs/cassava-sciences-sava-receives-a-buy-from-b-riley-financial-2?utm_source=advfn.com&utm_medium=referral
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Cassava Sciences Charts.